Last edition
News about
Atossa Therapeutics receives US Food and Drug Administration (FDA) Rare Pediatric Disease designation for (Z)-Endoxifen in McCune-Albright syndrome, qualifying for Priority Review Voucher award upon approval.
Accord Healthcare US Relaunches Tadalafil Tablets with Expanded Dosage Availability
Accord Healthcare US relaunches Tadalafil tablets with expanded dosage strengths to improve access for treating Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH), including ED/BPH combination therapy.
Olympus Corporation Partners EndoRobotics to Advance Robot-Assisted Endoscopy Globally
The Olympus–EndoRobotics partnership marks a significant step in advancing robot-assisted endoscopy, enabling more precise, minimally invasive treatment of gastrointestinal diseases worldwide.
Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118
Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.
Australia Approves First-in-Class Niktimvo for Chronic GVHD Treatment
Niktimvo approval marks a major breakthrough in treating chronic GVHD, introducing a first-in-class targeted therapy for patients with limited treatment options and high unmet medical need.
Ascidian Therapeutics Completes STELLAR Trial Dose Escalation for ACDN-01 in Stargardt Disease
Ascidian Therapeutics completes Phase 1/2 STELLAR dose escalation for ACDN-01 in Stargardt disease, advances pediatric enrollment, and launches STARPATH prescreening to accelerate clinical trial access.
Evotec SE and Almirall S.A. Advance Dermatology Drug Candidate to Preclinical Stage
The Evotec–Almirall collaboration showcases the power of AI-driven drug discovery, rapidly advancing a promising dermatology candidate toward clinical development for unmet medical needs.
Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid
Lupin secures US Food and Drug Administration (FDA) approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), bioequivalent to Ravicti Oral Liquid.
Eton Pharmaceuticals Relaunches HEMANGEOL (Propranolol) Oral Solution
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Anovo Specialty Pharmacy distribution and Eton Cares support, improving access to the only FDA-approved treatment for infantile hemangioma.
Brenig Therapeutics will showcase its hybrid AI drug discovery platform at the Keystone Symposia, with Dr. Alexei Pushechnikov highlighting its collaboration with Expert Systems, Inc.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy